News

The highlights of market news and industry events

 
10
JUL
2013

DEX-M74 Licensing

NZP is presenting on the application of DEX-M74 ManNAc as a potential therapy for HIBM (GNE myopathy) and kidney glomerular diseases at the NCATS R&D Day on Thursday, September 12, 2013 at the Novartis Institutes for Biomedical…

07
MAY
2013

US Patent Issued

New Zealand Pharmaceuticals Ltd is pleased to announce that the U.S. patent 8,410,063, entitled “N-acetyl mannosamine as a therapeutic agent” was issued on April 2, 2013. The invention relates to compositions and methods for treating…

14
FEB
2013

Applications of ManNAc

The application of N-acetylmannosamine to the mammalian cell culture production of recombinant human glycoproteins Selwyn C Yorke Keywords: N-acetylmannosamine, sialylation, glycoproteins. This mini-review covers recent…

08
FEB
2013

Certified ISO 14001

New Zealand Pharmaceuticals Ltd is proud to announce that is has been audited by TELARC and achieved its first ISO 14001 certification. In 2010, NZP implemented a specific program within the company to manage the environmental…

07
FEB
2013

Informex 2013

We are pleased to announce that Dextra laboratories Ltd and NZP will attend Informex USA 2013 in Anaheim CA, on February 20 & 21, 2013. Please arrange to meet us by direct email contact to informex2013@DextraUK.com, to discuss the…

04
DEC
2012

Tax Credit Certificate -

NZP is pleased to announce that Dextra has just received the French Ministére de L’Enseignement Supérieur et de la Recherche Tax Credit certificate. This is good news for any business from French companies as they will…

20
NOV
2012

Safety Milestone Reached

New Zealand Pharmaceuticals Ltd Celebrates One Million Hours of No Lost Time New Zealand Pharmaceuticals Ltd (NZP), a global leader in Bile Acids manufacturing has proven itself to be a model for safety with August 27th, 2012…

21
OCT
2012

New Research Published

New research published on potential mannosamine therapy for HIBM (GNE myopathy) and kidney glomerular disease “Oral monosaccharide therapies to reverse renal and muscle hyposialylation in a mouse model of GNE myopathy”, T. K.…

28
SEP
2012

Phase I Clinical Trial

New Zealand Pharmaceuticals Ltd Announces a phase I clinical trial using DEX-M74 to treat a rare degenerative muscle disease Palmerston North, New Zealand, September 26, 2012 — New Zealand Pharmaceuticals Ltd (NZP), a…

28
SEP
2012

Trial for Rare Disease

Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from…

12
JUN
2012

NZP at NZBio 2012

NZP’s CEO, Andy Lewis, will be a plenary speaker at the NZ Bio conference on Tuesday 27 March 2012, www.nzbio2012.co.nz to discuss the development of NZP’s new drug candidate, DEX-M74 to treat Hereditary Inclusion Body Myopathy…

28
FEB
2012

Patients with HIBM

The U.S. National Institutes of Health Clinical Center (NIH CC) in Bethesda, Maryland, U.S. is running a natural history study on patients with hereditary inclusion body myopathy (HIBM). This study is a pre-requisite for patients…

15
DEC
2011

Orphan Drug Designation

New Zealand Pharmaceuticals Ltd receives Orphan Drug Designation from the U.S. Food and Drug Administration for DEX-M74, a Treatment for Hereditary Inclusion Body Myopathy (HIBM) Palmerston North, New Zealand, December 15,…

17
AUG
2011

NHGRI Collaboration

New Zealand Pharmaceuticals Announces Collaboration with the NHGRI to Develop DEX-M74 as a Treatment for Hereditary Inclusion Body Myopathy (HIBM) Palmerston North, New Zealand, May 19, 2011 — New Zealand Pharmaceuticals Ltd…

16
AUG
2011

NZP Scholarships

NZP 300-level Bursary The Bursary was awarded jointly to Heather Jameson and David Nixon. Both these candidates attended secondary school in Palmerston North and then chose to study at Massey University because of the opportunity to…

29
APR
2011

Waste Water Discharge

The end of New Zealand Pharmaceuticals' wastewater discharge directly into the Manawatu River is a milestone for the waterway. The Linton factory has spent $2.5 million on its own settling tank to pretreat water used in washing…

01
JAN
2011

Sustainability Program

NZP has always endeavoured to engage in sustainable business practices, recognizing that potentially, without intervention, demand will eventually exceed supply of eco-system resources. Interestingly, NZP itself was built on…